



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Monetary costs and hospital burden associated with the management of invasive fungal infections in Mexico: a multicenter study

Dora Edith Corzo-León^{a,*}, Diana Perales-Martínez^b, Alexandra Martin-Onraet^c, Norma Rivera-Martínez^d, Adrian Camacho-Ortiz^e, Hiram Villanueva-Lozano^e

^a University of Aberdeen, Wellcome Trust Strategic Award, Medical Research Centre for Medical Mycology, Aberdeen, United Kingdom

^b Hospital Regional de Alta Especialidad del Bajío, Servicio de infectología y trasplantes, Guanajuato, Mexico

^c Instituto Nacional de Cancerología, Servicio de infectología y microbiología, Ciudad de México, Mexico

^d Hospital Regional de Alta Especialidad de Oaxaca, Servicio de infectología y microbiología, Oaxaca, Mexico

^e Hospital Universitario “Dr. José Eleuterio González” UANL, Servicio de infectología, epidemiología hospitalaria y microbiología, Nuevo León, Mexico

ARTICLE INFO

Article history:

Received 7 August 2018

Accepted 14 October 2018

Available online 2 November 2018

Keywords:

Fungal infections

Antifungal therapy

Cost

Acute kidney injury

Incidence rate

Mexico

ABSTRACT

Background: Invasive fungal infections (IFIs) affect >1.5 million people per year. Nevertheless, IFIs are usually neglected and underdiagnosed. IFIs should be considered as a public-health problem and major actions should be taken to tackle them and their associated costs. Aim To report the incidence of IFIs in four Mexican hospitals, to describe the economic cost associated with IFIs therapy and the impact of adverse events such as acute kidney injury (AKI), liver damage (LD), and ICU stay.

Methods: This was a retrospective, transversal study carried-out in four Mexican hospitals. All IFIs occurring during 2016 were included. Incidence rates and estimation of antifungal therapy's expenditure for one year were calculated. Adjustments for costs of AKI were done. An analysis of factors associated with death, AKI, and LD was performed.

Results: Two-hundred thirty-eight cases were included. Among all cases, AKI was diagnosed in 16%, LD in 25%, 35% required ICU stay, with a 23% overall mortality rate. AKI and LD showed higher mortality rates (39% vs 9% and 44% vs 18%, respectively, $p < 0.0001$). The overall incidence of IFIs was 4.8 cases (95% CI = 0.72–8.92) per 1000 discharges and 0.7 cases (95% CI = 0.03–1.16) per 1000 patients-days. Invasive candidiasis showed the highest incidence rate (1.93 per 1000 discharges, 95% CI = –1.01 to 2.84), followed by endemic IFIs (1.53 per 1000 discharges 95% CI = –3.36 to 6.4) and IA (1.25 per 1000 discharges, 95% CI = –0.90 to 3.45). AKI increased the cost of antifungal therapy 4.3-fold. The total expenditure in antifungal therapy for all IFIs, adjusting for AKI, was \$233,435,536 USD (95% CI \$6,224,993 to \$773,810,330).

* Corresponding author.

E-mail addresses: r01dec17@abdn.ac.uk, cold200781@gmail.com (D.E. Corzo-León).

<https://doi.org/10.1016/j.bjid.2018.10.277>

1413-8670/© 2018 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Conclusions: IFIs are as frequent as HIV asymptomatic infection and tuberculosis. Costs estimations allow to assess cost-avoidance strategies to increase targeted driven therapy and decrease adverse events and their costs.

© 2018 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Invasive fungal infections (IFIs) affect more than 1.5 million people per year, which is similar to the burden of infections due to tuberculosis and 3-fold more than malaria.¹ Despite this, IFIs are usually neglected and underdiagnosed especially in low- and middle-income countries, including those with endemic mycoses. The principal reasons for misdiagnosing are the absence of diagnostic tools plus insufficient training of health-care staff.^{2,3}

The lack of diagnostic tests based on culture and non-culture techniques, can lead to overuse of empirical therapy, mainly for individuals with hematological diseases and critically ill patients.^{4,5} Previous European reports have shown that antifungals are initiated as empirical therapy in more than 60% of the cases, which could lead to toxic adverse effects associated to unnecessary therapy and to higher costs.^{6,7}

IFIs should be considered as a public health problem, therefore a number of major actions should be taken to address these infections and their associated costs. These actions include insurance coverage of affordable diagnostic tests, improvement of mycology expertise across low- and middle-income countries' diagnostic laboratories, safeguarding the distribution of essential antifungal agents, establishment of an official reporting and surveillance system for these infections.^{3,8} These measures are also key elements of an effective antifungal stewardship program.⁹

In this study, we report the incidence rates of IFIs in four Mexican hospitals, describe the economic cost associated with IFIs therapy and the impact of adverse events such as acute kidney injury, liver damage, and ICU stay.

Methods

Setting

Mexico has a divided health system where public health care is furthered divided into people with and without social insurance. Uninsured Mexicans' health expenditure can be out of pocket or covered by the Seguro Popular (SP). The SP consists of well defined benefit packages and medicines that provides coverage only for certain services such as preventive medicine and primary care, national vaccination program, HIV infection care, and catastrophic medical expenditures associated with certain conditions such as critical care, neonatal care, congenital disorders, certain malignancies, hepatitis C infection, stem-cell, and solid-organ transplants (with different limitations regarding age).¹⁰

Participating centers

Four hospitals located in different states around the country that provide medical attention to patients without social security were included.

In all the hospitals, patients' socioeconomic level (SEL) was evaluated upon admission and many of the expenses are charged according to the socioeconomic level.

The National Cancer Institute (INCan) of Mexico City is a 150-bed tertiary care center focused on the treatment of adult oncological patients who are referred mostly from the central part of the country for medical attention. For diseases not included in the SP, hospital expenses are paid according to the SEL assigned, but medication costs are absorbed 100% by the patient, regardless of SEL.

The Regional High Specialty Hospital of Oaxaca (HRAEO) is a 100-bed tertiary care center located in Oaxaca City, Southwest Mexico. It provides service only to adults, without gynecology and obstetrics department. The patients pay the hospital length of stay (LOS) and procedures according to the assigned SEL, the rest is absorbed by the hospital. The costs of drugs included in the basic hospital chart, are 100% absorbed by the hospital.

The University Hospital "Dr. José Eleuterio González" (HUNL) is a 667-bed general hospital in Nuevo León, Northeast Mexico. The hospital is part of the Autonomous University of Nuevo León, providing total hospital attention to around 50% of the patients without medical insurance in the entire state. Patients treated in the hospital are predominantly from Nuevo León and surrounding Northeast states. All expenses are paid according to the SEL.

The Regional High Specialty Hospital of El Bajío (HRAEB), in León Guanajuato, North Central Mexico, is a 184-bed tertiary care center, specialized in adult oncological patients as well as hematopoietic, renal and hepatic transplantation, and highly specialized surgery. Patients are referred from the middle and east part of the country. Almost 100% of them have SP, and more than half of them are covered by the catastrophic funding; total expenses of hospitalization and medication costs are absorbed 100% by federal government. In all the hospitals, patients with diseases not covered by SP or catastrophic diseases pay hospital expenses according to the SEL, and purchase medications not provided by the hospital at full cost.

Study design and data collection

This was a retrospective and cross-sectional study approved by each local institutional review board (IRB) with the

following register numbers: HUNL IF17-00001, HRAEB CEI-08-17, INCAN CI/381/17 and HRAEO-CIC 003-17.

All IFIs occurring during 2016 were identified using the databases of each participating hospital. Clinical data was recovered from medical records. This included demographic information, previous comorbidities, type of IFI, antifungal type used, duration, and indication, as well as, outcomes such as development of acute kidney injury (AKI), liver damage (LD), ICU admission, hospital LOS, and mortality.

The following definitions were used:

- AKI was defined as a \geq two-fold increase in serum creatinine compared to baseline level and/or presence of hypokalemia, or hypomagnesaemia during antifungal therapy.
- LD was defined as a \geq two-fold increase in AST/ALT or total bilirubin compared to baseline level during antifungal therapy.
- IFIs were classified according EORTC/MSG criteria.¹¹ Possible IFIs were categorized as possible IFIs in neutropenic fever (NF) individuals or possible IFIs in non-NF individuals.

Data regarding costs of antifungal drugs, hospital, and ICU stay were provided by each participant hospital for each patient. In Mexico, hospitals buy certain authorized antifungal drugs at pre-established prices during public tenders (Supplementary material, Table S1). Antifungals such as liposomal amphotericin B (LAmB) and posaconazole are usually not part of the hospitals' stock due to their high prices. Hence, LAmB should usually be purchased by the patients at drug stores or via a non-governmental organizations (NGOs). Estimate expenses for antifungals were calculated based on the prices paid by each hospital (Table S1).

All identified IFI-cases without clinical data available were not included for either clinical nor cost analysis, however they were included for incidence rates calculation.

Incidence rates estimation

Only proven and probable IFIs were used to estimate incidence rates. These were calculated by type and an overall incidence rate for all types of IFIs. The incidence rates were estimated using the number of discharges and patients-days during 2016.

Cost of IFIs analysis per year in Mexico

An estimation of the total expenditure in antifungal therapy during one year in Mexico was performed based on the number of hospital discharges during 2015 (last information available). This information, was gathered from the Organization for Economic Cooperation and Development (OECD) webpage, in December 2017.¹² The rest of the estimations was calculated with data obtained in this study, such as incidence rate for proven/probable IFIs, mean cost of antifungal therapy, mean days of treatment. Costs were adjusted by the expected proportion of AKI and increasing cost of antifungal therapy due to AKI.

Statistical analysis

This study data is presented as proportion, median and interquartile range (IQR) depending on the type of data. For categorical data comparisons, Pearson's chi-square or Fisher's exact test were used as appropriate and for ordinal and quantitative variables, Mann-Whitney or Kruskal-Wallis tests were used as indicated. After univariate analysis, those variables with a p -value ≤ 0.05 were included in a binary logistic regression multivariate analysis of factors associated with death, AKI and LD, and adjusted for sex and age. Statistical analysis and plot construction were performed using SPSS 24 (IBM Chicago, US) and Prism 7 (Graph Pad, California, US) software. Mean and 95% confidence intervals were estimated as required for the yearly expenditure analysis and incidence rates.

Results

General characteristics of the population

A total of 238 cases were included in the analysis. Most of the cases had a hematological malignancy (34%), followed by a solid tumor (16%), diabetes mellitus (10%) and HIV infection (8%) (Table 1). The main indication for antifungal therapy in this sample was empiric in 59% (140/238) of the cases, most of them to treat possible IFIs in non-neutropenic individuals (101/140, 72%); in the remaining 41% the indication was to treat proven or probable IFI (Table 1). Ninety-four percent of the individuals with a NF-possible IFI (37/39) had a hematological malignancy and/or solid tumor. In contrast, only 33% of the individuals with a non-NF possible IFI had either these comorbidities (Table S2).

AKI was diagnosed in 16% (39/235) of the cases during antifungal therapy, whereas LD was identified in 25% (58/235), ICU stay was required in 35% (83/238), and the mortality rate was 23% (54/229 cases) (Table 1). No difference in mortality was seen by type of proven/probable IFI (Figure S1). However, compared with possible IFIs (NF and non-NF) the mortality rate was higher for proven/probable IFIs as group (29/91, 32% vs 25/138, 18%, $p = 0.025$) (Table S2).

Type of IFIs, characteristics and incidence rates

There were 98 cases of proven/probable and 140 possible IFIs, 39 in neutropenic and 101 in non-neutropenic individuals. The proven/probable IFIs were categorized into four groups: invasive candidiasis (IC), invasive aspergillosis (IA), endemic IFIs (coccidioidomycosis and histoplasmosis), and other IFIs (cryptococcosis, mucormycosis, fusariosis, non-specified IFIs). IC was the most frequent IFI overall (32/98, 33%), followed by IA (22/98, 23%), and histoplasmosis (19%) (Fig. 1A). Upon patients' subgroups analysis, aspergillosis, was the most frequent proven/probable IFI among individuals with a hematological malignancy (18/40, 45%), and endemic IFIs (histoplasmosis and coccidioidomycosis) were more frequently seen in the HIV subpopulation (11/19, 58%) (Fig. 1B).

The overall, IFI incidence was 4.8 cases (95% CI = 0.72–8.92) per 1000 discharges and 0.7 cases (95% CI = 0.03–1.16) per

Table 1 – General characteristics of the studied population in four Mexican hospitals.

Characteristic	N=238 (%)
Age, yrs (median, IQR)	37 (22–54)
Female sex	105 (44)
Comorbidities	
Hematological malignancies	80 (34)
Lymphocytic acute leukemia	28/80 (35)
Myeloid acute leukemia	23/80 (29)
Other	29/80 (36)
Solid neoplasia	38 (16)
Diabetes mellitus	25 (10)
HIV infection	20 (8)
Autoimmune disease	13 (5.5)
Heart disease	13 (5.5)
Renal transplant	13 (5.5)
Other (hepatic cirrhosis or other gastrointestinal disease, and neurologic, genitourinary diseases)	36 (15)
Primary indication for Antifungal therapy	
Non-NF possible IFI	101 (42.5)
Proven/probable IFI	98 (41)
Neutropenic fever possible IFI	39 (16.5)
First antifungal used (before having the final diagnosis)	
Fluconazole	85 (36)
Echinocandins (casposfungin, anidulafungin)	68 (29)
AMBD	38 (16)
Voriconazole	19 (8)
Lipid formulation of AMB	13 (5)
Other (posaconazole, itraconazole)	12 (5)
Second antifungal used (N=80/235, 33%) (adjusted management)	
Fluconazole	23 (29)
Voriconazole	15 (19)
Casposfungin	10 (13)
Itraconazole	10 (13)
Lipid formulation of AMB	8 (11)
AMBD	7 (9)
Duration of antifungal therapy (days, median, IQR)	10 (5–18)
Acute kidney injury^b	39 (16)
Liver damage during antifungal treatment (LD)^b	58 (25)
Length of hospital stay (days, median, IQR)	20 (12–31)
ICU stay	83 (35)
Length of ICU stay (days, median, IQR)	11 (5–19)
Mortality rate^c	54 (23)
Total cost of antifungal drug (US dollars, median, IQR)^a	232 (8–1044)
Total cost associated with hospital stay (US dollars, median, IQR)^a	410 (124–1099)

IFI, invasive fungal infection; IQR, interquartile range; NF, neutropenic fever.
 Currency: \$20 Mexican peso by \$1 US dollar (USD).
 AMBD, amphotericin B deoxycholate.
^a Estimated cost per treated person, for one treatment.
^b Estimated proportion using 235 treated cases.
^c Estimated proportion using 229 cases with information available about this outcome.

1000 patients-days. IC had the highest incidence rates (1.93 cases per 1000 discharges, 95% CI=−1.01 to 2.84), followed by endemic IFIs (1.53 per 1000 discharges 95% CI=−3.36 to 6.40) and IA (1.25 per 1000 discharges, 95% CI=−0.90 to 3.45) (Table 2).

Based on these incidence rates, and according to the total number of hospital discharges (6,269,155) reported by the OCDE in Mexico during 2015, the number of new cases of IC per year would be 12,103 (95% CI=3621–20,584), for IA 7851 (95% CI=−5918 to 21,621), for endemic mycosis 9598 (95% CI=−21,034 to 40,265). Taking into account the total Mexican population (127.5 million), the incidence rate of these infections would be approximately 9.49 (95% CI=2.84–16.00), 6.15 (95% CI=−4.64 to 16.96), 7.52 (95% CI=−16.49 to 31.58) per 100,000 inhabitants for IC, IA, and endemic mycosis, respectively.

No differences in AKI or LD rates were found among the type of proven/probable IFIs, not even among survivors (Table S4). Intensive care unit admission was more frequent in patients with IC (17/32, 53%), endemic IFIs (27%, 6/22), and other IFIs (18%, 4/22). For aspergillosis, ICU stay was required only in 9% of the cases (2/22), $p < 0.002$, no differences were found when only survivors were analyzed (Table S4).

Characteristics of the antifungal therapy used

Fluconazole and echinocandins were the two most frequently indicated antifungal drug as initial therapy (Table 1). Only three out of 238 individuals did not receive the indicated antifungal therapy. Seventy-three percent of the IC cases received an echinocandin as main therapy (22/30), while for IA, voriconazole (11/22, 50%) and amphotericin B deoxycholate (6/22, 27%) were the preferred options, as for the cases with endemic and other IFIs, AMBD was the leading therapy (20/43, 46%), in these cases lipid formulation of amphotericin B was used only in 7 of 43 cases (16%).

IC required the shortest duration of antifungal therapy (median 14 days, IQR 10–18) compared with the rest of the proven/probable IFIs groups (IA=median 23 days IQR 9–59; endemic IFIs=median 15 days IQR 10–91, and other IFIs=median 34 days IQR 17–68, $p = 0.05$) (Fig. 2A). This difference was more evident ($p < 0.0001$) when the antifungal therapy period was analyzed only among survivors. All in all, groups with longer antifungal therapy were endemic IFIs (median 91 days, IQR 14–259), followed by other IFIs (median 53 days, IQR 24–68), and IA (median 56 days, IQR 33–74) when compared with IC (median 14 days, IQR 11–22) (Fig. 2B).

Clinical characteristics of patients developing acute kidney injury and liver damage during antifungal therapy

The development of AKI and LD was associated with higher mortality rate (39% vs 9% and 44% vs 18%, respectively, $p < 0.0001$). These adverse events, in a multivariate binary regression analysis, were associated with death, independently of ICU stay, age, and sex (Table S5). In this model, AKI development was associated with a four-fold higher probability of dying (OR=4.29, 95% CI=1.80–10.02, $p = 0.001$), and LD was associated with double the probability (OR=2.34, 95% CI=1.13–4.85, $p = 0.02$).




Fig. 1 – (A) Proven/probable infections identified during 2016 in four Mexican hospitals. Ninety-eight proven/probable IFIs were identified. Unspecified IFIs refers to diagnosis by histopathology without etiological identification. (B) Distribution of IFIs by clinical context. The frequency of the proven/probable IFIs varied depending on the comorbidity. Other IFIs includes: cryptococcosis, mucormycosis, cladosporidosis, fusariosis, pneumocystosis, and unspecified IFIs.

In the overall population, the antifungal drug was modified in 80/235 (34%) cases due to different causes, such as AKI (20/80, 25%), de-escalation or adjusting to diagnosis (60/80, 75%) (Table 1).

In this study, survivors (n = 175) were defined as those who received a complete antifungal therapy scheme. In this subgroup, AKI was more frequent in cases of proven/probable IFIs (11/62, 18%) than in cases of NF and non-NF possible IFIs (2/31, 6% and 3/82, 4%, p = 0.01) (Table S3). This pattern was similar in all groups regarding LD during the antifungal therapy (28% vs 13% vs 12%, respectively, p = 0.03) (Table S3). Among survivors who developed AKI, 31% had received AmBD and 25% LAmB as first antifungal, these proportions were higher

compared with 14% and 2.6%, respectively, for the individuals without AKI (p < 0.0001) (Table 3). Survivors who developed AKI received longer antifungal therapy (median 18 days IQR 14–50 vs median 10 days IQR 6–17, p = 0.0008), had longer hospital stay (median 27 IQR 18–40 vs median 19 days IQR 12–31, p = 0.05), and higher probability of ICU admission (63% vs 27%, p = 0.008) (Table 3). The group developing LD also received longer antifungal therapy (median 15 days IQR 5–17 vs median 10 IQR 5–17, p = 0.001), had longer hospital stay (median 28 IQR 20–38 vs 18 IQR 12–30, p = 0.003), and ICU admission (48% vs 27%, p = 0.03) (Table 4).




Fig. 2 – (A) Time of antifungal therapy in proven/probable fungal infections in the total population. *p value = 0.046. Invasive candidiasis n = 32, aspergillosis n = 21, endemic (histoplasmosis/coccidioidomycosis) n = 21, other IFI n = 21. (B) Time of antifungal therapy in proven/probable fungal infections among survivors. p value = 0.002. *p = 0.006 invasive candidiasis vs aspergillosis, **p = 0.002 invasive candidiasis vs endemic, *p = 0.006. Candidiasis n = 22, aspergillosis n = 12, endemic n = 11, other IFI n = 14. Data presented as median and IQR. Data analyzed with Kruskal-Wallis test. Post hoc analysis was done with Dunn’s test.**

Table 2 – Incidence rates per 1000 discharges and per 1000 patients-days.

Type of IFI	Per 1000 discharges (95%CI)	Per 1000 patients-days (95% CI)
Invasive candidiasis	1.93 (1.01 to 2.84)	0.36 (0.06 to 0.67)
Coccidioidomycosis/histoplasmosis	1.53 (–3.36 to 6.4)	0.24 (–0.47 to 0.94)
Aspergillosis and other hyalophyphomycosis	1.25 (–0.90 to 3.45)	0.23 (–0.14 to 0.61)
Mucormycosis	0.33 (0.08 to 0.58)	0.06 (–0.12 to 0.25)
All IFIs	4.8 (0.72 to 8.92)	0.7 (0.03 to 1.16)

Table 3 – Characteristics in AKI and non-AKI in survivors.

Characteristic	Univariate analysis			Multivariate analysis		
	Non-AKIN = 159	AKI N = 16	p value	OR	95% CI	p value
Age, yrs (median, IQR)	37 (21–54)	28 (24–56)	0.95	1.00	0.97–1.03	0.94
Sex (female)	76 (48)	5 (31)	0.29	0.50	0.12–2.03	0.33
Comorbidities						
Hematological condition	48 (30)	5 (31)	0.8			
Solid neoplasia	33 (21)	1 (6)				
Diabetes mellitus	15 (9)	2 (12)				
HIV infection	8 (5)	1 (6)				
Renal transplant	10 (6)	1 (6)				
Other	45 (29)	6 (37)				
First antifungal used						
Fluconazole	68 (43)	0	<0.0001	24.94 ^b	4.2–137	<0.0001
Caspofungin	29 (18)	5 (31)				
AMBD	22 (14)	6 (31)				
Anidulafungin	20 (13)	0				
Lipid formulation of AMB	4 (2.6)	4 (25)				
Need of a second antifungal	48 (30)	10 (62)	0.01			
Time of antifungal treatment (days, median, IQR)	10 (6–17)	18 (14–50)	0.008	0.99	0.99–1.00	0.76
Length of hospital stay (days, median, IQR)	19 (12–31)	27 (18–40)	0.05	0.99	0.97–1.02	0.365
ICU stay	43 (27)	10 (63)	0.008	17.98	3.2–100	0.001
Length of ICU stay (days, median, IQR)	14 (7–20)	5 (2–11)	0.02			
Total cost of antifungal drug (US dollars, median, IQR) ^a	246 (9–874)	1048 (729–6543)	<0.0001			
Total cost associated with hospital stay (US dollars, median, IQR) ^a	325 (109–1003)	680 (335–1063)	0.04			

^a Estimated cost per treated person.

^b Amphotericin vs non-amphotericin (any formulation) use.

Multivariate analysis model, $X^2 = 31$, $DF = 6$, $p < 0.0001$, sensitivity 93%.

Table 4 – Characteristics of non-liver damage (LD) vs LD survivors.

Characteristic	Univariate analysis			Multivariate analysis		
	No-LDN = 142	LDN = 31	p value	OR	95% CI	p value
Age, yr (median, IQR)	38 (21–53)	31(26–58)	0.68	1.00	0.97–1.03	0.53
Sex (female)	66 (46)	14 (45)	1	1.27	0.54–3.0	0.57
Comorbidities						
Hematological condition	39 (27)	14 (45)	0.46			
Solid neoplasia	28 (20)	6 (19)				
Diabetes mellitus	13 (9)	2 (6.5)				
HIV infection	8 (6)	1 (3)				
Renal transplant	10 (7)	1 (3)				
Other	44 (32)	6 (19)				
First antifungal used						
Fluconazole	65 (46)	3 (10)	0.008	212 ^b	0.74–6.03	0.16
Caspofungin	26 (18)	7 (23)				
AMBD	19 (13)	8 (26)				
Anidulafungin	14 (10)	6 (19)				
Lipid formulation of AMB	6 (4)	2 (7)				
Voriconazol	7 (5)	5 (16)				
Time of antifungal treatment (days, median, IQR)	10 (5–17)	15(10–46)	0.001	1.00	0.99–1.01	0.12
Length of hospital stay (days, median, IQR)	18 (12–30)	28 (20–38)	0.003	1.00	0.99–1.02	0.18
ICU stay	38 (27)	15 (48)	0.03	2.92	1.18–7.17	0.02
Length of ICU stay (days, median, IQR)	13 (5–20)	11 (7–19)	0.98			
Total cost of antifungal drug (US dollars, median, IQR) ^a	194 (8–818)	835 (403–1407)	0.001			
Total cost associated with hospital stay (US dollars, median, IQR) ^a	337 (111–957)	327 (123–1499)	0.25			

^a Estimated cost per treated person

^b Amphotericin vs non-amphotericin (any formulation) use.

Multivariate analysis model, $X^2 = 14$, $DF = 6$, $p = 0.03$, sensitivity 82%.

Table 5 – Increasing cost associated with AKI development during antifungal therapy.

All population		Cost of antifungal treatment ^a			p value ^b
Condition	Proven/probable IFI	NF possible IFI	Non-NF possible IFI		
Non-AKI (n = 180)					
Median	\$907	\$75	\$28		<0.0001
IQR	(178–1843)	(7–192)	(6–642)		
AKI (n = 38)					
Median	\$343	\$512	\$524		NS
IQR	(7–1875)	(111–858)	(112–2384)		
Survivors		Cost of antifungal treatment ^a			p value ^b
Condition	Proven/probable IFI	NF possible IFI	Non-NF possible IFI		
Non-AKI (n = 147)					
Median	\$1044	\$70	\$27		<0.0001
IQR	(356–1599)	(5–142)	(6–642)		
AKI (n = 16)					
Median	\$1414	\$858	\$835		NS
IQR	(812–6543)	(808–908)	(679–4977)		

^a Costs in US dollars, per treated person.

^b Kruskal–Wallis test.

Associated cost with antifungal therapy and length of hospital stay

The cost per unit of IV fluconazole and oral formulation varied between 0.4 and 1.2 USD, which represents the antifungal with the lowest cost per unit. The most expensive antifungals, per unit, were posaconazole (\$558–766) and LAmB (\$154–230) (Table S1).

The cost per day of antifungal per person was \$11 USD (IQR 1–104). However, the cost varied depending on the type of antifungal drug used. The median costs per treated person were \$7 (IQR 4–16) for fluconazole, \$654 (218–1817) for voriconazole, \$731 (IQR 522–1044) for caspofungin, \$612 (IQR 349–1136) for anidulafungin, \$96 (IQR 36–375) for AmBD, and \$6840 (IQR 3040–9120) for LAmB ($p < 0.0001$).

When the cost of antifungal therapy was analyzed by type of proven/probable IFI, among survivors, the group of other IFIs had the highest cost per treated person (\$1843, IQR 567–46,543) followed by IA (\$1382, IQR 645–2924), and IC (1072, IQR 528–1461), whereas endemic IFIs showed the lowest cost per treated person (\$266, IQR 163–546), $p = 0.015$ (Table S4).

Patients with AKI needed a second antifungal more frequently (30%) than those without AKI (54%) [$p = 0.008$], and this difference was more evident in individuals who survived (30% vs 62%, $p = 0.01$) (Table 3). The presence of AKI increased 4.3-fold the cost of antifungal therapy (median \$246 IQR 9874) when compared with individuals without AKI (median \$1048 IQR 729–6543) [$p < 0.0001$] (Table 2). This increase in cost was mainly due to the cases with possible IFIs, between 7- (for cases of NF possible IFIs) and 18-fold ((for cases of non-NF possible IFIs) when all cases were analyzed (Table 5). However, the costs increased between 12- and 31-fold when the analysis was restricted to survivors, for non-NF and NF possible IFIs, respectively (Table 5).

Also, LD had a 4-fold increase in the cost of antifungal therapy (Table 3). Similarly, to AKI, the costs increased for non-NF

and NF possible IFIs cases between 30- to 58-fold, and between 35- and more than 200-fold increase among survivors with non-NF and NF possible IFIs cases, respectively.

Mexican health system estimated expenditure in antifungal therapy in a one-year span

Information about the costs of the antifungal therapy and length of hospital stay provided by each hospital and case-specific allowed to determine the mean cost of a day of antifungal therapy and hospital-stay (Table 6). These values could vary, depending on the type of antifungal drug (more expensive for liposomal amphotericin B and less expensive for generic formulations of fluconazole), required doses, ICU stay, and if the patient died or survived. In order to have an approximated mean cost of the antifungal therapy, all different drug costs for all patients were taken into account, without distinction with regard to the final outcome (Table 6).

The total number of hospital discharges in Mexico was obtained from the OECD webpage.¹² The last information available corresponded to 2015 for the hospital discharges by diagnostic categories. A total of 6,260,155 hospital discharges were reported by OECD during that year. Taking into account, the proven/probable IFI incidence rate estimated in this study, 4.8 per 1000 discharges (95% CI 0.7–8.9), we estimate that in one year the total number of proven/probable IFIs treated with an antifungal drug to be approximately 30,091 patients (95% CI 4396–55,785) (Table 6). However, based on our data (showed above), these numbers correspond only to 41% of the cases receiving an antifungal drug (Table 1). Hence, the total number of individuals who received an antifungal drug due to any type of IFI (proven/probable/possible) in one year would be 66,510 individuals (95% CI, 3930–130,602). This estimated burden represents an approximation to the total use of antifungal therapy in Mexico.

Taking into account the data expressed in this study, the estimated mean duration of one antifungal therapy for any

Table 6 – Antifungal and hospital stay costs of IFIs in Mexico.

Costs per day ^a	Value		
Daily cost of antifungal therapy	93 (61–124)		
Mean value (\$), 95% CI			
Cost per day in hospital	25 (19–31)		
Mean value (\$), 95% CI			
Daily ICU cost	90 (67–112)		
Mean value (\$), 95% CI			
Treatment duration, days (mean, 95% CI)	25 (17–33)		
Type of IFI indicating antifungal therapy	Proven/probable IFI	NF-possible IFI	Non-NF possible IFI
Estimated number of people receiving antifungal therapy in one year ^b (number, 95% CI)	30,091 (4396–55,785)	12,109 (1769–22,450)	31,191 (4556–55,785)
Treatment duration, days (mean, 95% CI)	48 (30–66)	11 (8–14)	9 (7–10)
Rate of AKI	27%	10%	9%
Rate of LD	34%	26%	15%
Increasing antifungal cost due to AKI	– ^c	12 times	31 times
Increasing hospital stay cost due to AKI	2 times	2 times	1.8 times
Proportion of increasing antifungal cost due to LD	^c	35 times	200 times
Proportion of increasing hospital stay cost due to LD	– ^c	2 times	2.7 times
Rate of ICU stay	29%	15%	47%
Increasing hospital stay cost due to ICU stay	3 times	2.5 times	7.5 times

^a Assumed cost and associated increasing were taken from the results obtained in the clinical and cost analysis presented in previous sections in this manuscript.

^b Taking into account incidence rate of IFIs (4.8 per 1000 discharges, 95% CI 0.7–8.9) and number of discharges during 2015 in Mexico. Number of discharges during 2015 = 6,269,155 (source: stats.oecd.org). Proven/probable IFIs was considered to be 41% of people receiving antifungal, NF-possible IFI 16% and non-NF possible IFI 42% of people receiving antifungals considering the results of this paper in Table 1.

^c No statistical significance in increasing cost was seen for proven/probable IFIs due to AKI and LD.

type of IFI was 25 days (95% CI 17–33). The mean cost of one treatment, therefore was \$1100 USD (95% CI 600–4488). However, the duration is usually longer in proven/probable IFIs (Table 6), especially for IA and endemic IFIs (>400 days in some cases) (Fig. 2). Hence, this estimate shown above could be even higher.

The total expenditure in antifungal therapy for all type of IFI, without adjusting for AKI, LD and ICU stay, would be approximately \$154,636,516 USD (95% CI \$4,075,571–\$534,423,801 USD). After adjustment only for the proportion of expected individuals to develop AKI and the increasing in antifungal cost in such cases, the expenditure in antifungal therapy for all type of IFI would ascend to \$233,435,536 USD (95% CI \$6,224,993 to \$773,810,330).

Discussion

Herein we report the characteristics of IFIs managed in four hospitals in Mexico and provide an estimate of the burden of IFIs in Mexico. The overall incidence rate of IFIs and more specifically the individual rates of aspergillosis, histoplasmosis, coccidioidomycosis and candidemia are shown here and, with the exception of invasive candidiasis, no similar study has been published in recent years.^{13,14}

Prior studies on coccidioidomycosis and histoplasmosis from Mexico have focused on the prevalence of these two

infections by using coccidioidin skin testing¹⁵ and not focused in the incidence of active infections.

In Mexico, notification of these IFIs to the national health ministry was discontinued in 1995.¹⁶ The last incidence rate reported for coccidioidomycosis and histoplasmosis in Mexico was 1.3 and 0.3 cases per 100,000 inhabitants, respectively.¹⁶ During 1995, in the US, the incidence of coccidioidomycosis was 1.9 cases per 100,000, which increased, since 1998, from 5.3 per 100,000 to 42.6 in 2011 and to 8.82 in 2015.^{17,18} Meanwhile, histoplasmosis incidence rate was maintained steady between <1 and 1.7 cases per 100,000 between 2001 and 2012.^{19,20}

In the current study, we estimated an incidence rate for endemic IFI of 7.5 per 100,000 inhabitants although it is possible that in Mexico, as for coccidioidomycosis in the US, the number of cases of these infections have increased since 1995.

Diagnostic improvement in IA has been in part due to the availability of galactomannan antigen detection in specialized reference centers, not only in Mexico, but in other Latin American countries.²¹ This is the first study reporting the incidence of aspergillosis in a Mexican population where rates are similar to previously published incidence rates in the US during 2009–2013, estimated to be 2 cases per 1000 discharges among individuals at risk.²²

In this study, that at least 30,000 new cases per year of proven/probable IFIs were estimated to have occurred in

Mexico. This estimation would be higher than the number of new cases officially reported by the Mexican health department during 2016 for Chikungunya, hemorrhagic Dengue, and Zika virus infections ($n=13,030$ cases), hepatitis A, B and C virus ($n=10,456$ cases), HIV asymptomatic infection ($n=7333$ cases), and tuberculosis ($n=20,811$ cases).¹⁶ We believe that with the estimated cases expressed here, IFIs should become a notifiable group of diseases and be treated as a public health problem.

The four hospitals included in this study have several differences, such as number of beds, patient diversity, geographic location, and policies about the reimbursement of expenses, mainly for antifungal drugs. The data presented in the study is heterogeneous, however, this heterogeneity is a rule more than an exception in Mexican hospitals. Nevertheless, we acknowledge limitations in the estimations showed in the current study, as these four hospitals only represent 0.3% out of the total hospitals in the public health care system and 0.5% of hospitals in the public health care system for those without institutional insurance, in Mexico.²³ These limitations could be surpassed if the notification of these infections becomes mandatory, and the access to better diagnostic tools is improved.

The diagnosis of possible IFIs, receiving empirical therapy, corresponds to more than half of the cases. This proportion can be the result of several phenomena. First, most of the proven/probable IFIs were diagnosed via culture techniques which are a low sensitivity diagnostic tool for IFIs. A classic example is IC, as blood culture identifies only two to seven out of 10 cases.²⁴ The capacity to diagnose this infection increases to eight to nine out of 10 cases when non-culture techniques are added to the diagnostic armamentarium, such as PCR and β -D-glucan assay.²⁴ In the case of histoplasmosis, the inclusion of training in diagnosis by direct examination, pathology and PCR showed a three-fold increase of reported cases in the French Guyenne as well as a decrease in mortality due to this infection from 40% to 10%.²⁵ In Mexico, as in other Latin American countries, culture-based diagnosis is not always available at second care level hospitals, expertise in histological examination of fungi is limited to high specialized referral centers, and non-culture techniques, other than galactomannan, are not available even at referral centers. Second, as the lack of access to better diagnostic tools decreases the possibility of accurate identification of IFIs, this also, may increase overdiagnosis and hence overuse of empiric antifungal drugs, causing unwanted adverse events such as AKI or LD, and higher costs for medical institutions and patients, as shown in this study.

Amphotericin B formulations, itraconazole, voriconazole, flucytosine, and fluconazole are in the Essential Medicine List issued by the WHO.²⁶ Except for flucytosine, these drugs are all listed as national essential drugs in Mexico.²⁶ In the participating hospitals in this study mostly of these drugs were available, except for LAmB, at different costs.

According to the Mexican universal list of health services (CAUSES), AmBD is considered essential in the management of fungal meningitis and pneumonia.²⁷ During 2016 and 2017, amphotericin B deoxycholate became unavailable

across the country, which led to a switch in the pattern of antifungal management. One of the changes brought by the lack of AmBD, during that period, was the inclusion of LAmB at a catastrophic cost. However, access to this drug is still problematic, not all patients are covered and, if it is needed, the cost is absorbed by the patient. As showed here and in previous studies,²⁸ the cost of LAmB per unit is at least 10-fold more expensive than AmBD, and usual dose per day is three-fold higher, >\$300 USD per day, which is 75-fold higher than the daily minimum wage in Mexico.²⁹ Besides the economic cost of antifungals, access is also a concern, owing to the limited number of manufacturers and/or distributors of these drugs.³⁰ In our country, currently, only two companies distribute generic AmBD and two distribute LAmB. At least five are licensed to distribute generic fluconazole, and one patent fluconazole.³¹ Unavailability of either amphotericin B or flucytosine impacts the prognosis of infections such as cryptococcus, histoplasma and mucormycosis meningitis, in addition to some resistant aspergillosis.^{30,32,33}

In this report, the estimated expenditure only with antifungal drugs in one year would represent 29% of the required annual budget to manage complications due to obesity.³⁴ The cost of antifungal therapy estimated in this study did not include costs associated with hospitalization, blood, and imaging tests, which are necessary to have a better panorama of the expenses due to IFIs. It is known that IFIs are an independent factor for higher associated health care costs.³⁵ Antifungal drugs increase at least 25% these costs and hospitalization costs can be 40% higher when an IFI is diagnosed, mainly for invasive candidiasis, aspergillosis and mucormycosis.³⁶ In-hospital LOS is longer for cases with IFIs. In our study, LOS was almost two-fold longer for aspergillosis and endemic mycosis when compared with reports from other countries.³⁷

This is the first study conducted in Mexico and Latin America analyzing the impact of AKI development during treatment of IFIs on the cost of antifungal therapy, LOS, and mortality rates. As previous reports have shown, in our study AKI was associated with higher mortality rate during IFIs therapy, usually associated with the use of amphotericin formulations.³⁸ Previous studies have identified AKI as independent factor associated with death in hospitalized patients, with a probability of death 3 to 26 times higher, similar to our findings.³⁹ As previously shown, AKI inflates the cost of the IFI therapy, between 1 and 7 times.^{38,39} In our data, such an increase was not restricted to AKI as LD also impacted the overall cost.

In this report, other contributing factors to AKI or LD were not assessed, which is a limitation inherent to the study design. Most of the individuals suffering from an IFI require multiple medications to treat comorbidities such as chemotherapy, antiretrovirals, or have underlining AKI such as diabetic patients, and could also be critically ill due to IFI or other conditions. We could not ascertain if AKI was secondary to the use of antifungal therapy since we did not control for other confounders, but we could establish the high burden and impact of AKI in patients with IFI, which justifies increasing focus on preventive measures.

Conclusion

Awareness of the burden of IFIs in Mexico and the estimation of the treatment cost per person, allowed us to have an approximate expenditure in antifungal drugs by the health care system. This estimation allows to assess cost-avoidance strategies, such as antifungal prophylaxis, antifungal stewardship, programs improving access to essential drugs and make cost-conscious decisions such as access to more diagnostic tools, to increase diagnostic-driven therapy and decrease unwanted adverse events and their associated cost.

Contributions

DECL contributed to the conception and design of the study, also to the analysis and interpretation of data, and drafting the manuscript. DPM, AMO, NRM, HVL contributed with acquisition of data, and drafting the manuscript. AMO and ACO contributed with critical revision of the manuscript, interpretation of data and drafting the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

The authors declare no conflicts of interest.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.bjid.2018.10.277>.

REFERENCES

- Bongomin F, Gago S, Oladele R, Denning D. Global and multi-national prevalence of fungal diseases—estimate precision. *J Fungi*. 2017;3:57.
- Tudela JLR, Denning DW. Recovery from serious fungal infections should be realisable for everyone. *Lancet Infect Dis*. 2017;17:1111–3.
- Denning DW. The ambitious “95–95 by 2025” roadmap for the diagnosis and management of fungal diseases. *Thorax*. 2015;70:613–4.
- Zein M, Parmentier-Decrucq E, Kalaoun A, et al. Factors predicting prolonged empirical antifungal treatment in critically ill patients. *Ann Clin Microbiol Antimicrob*. 2014;13:1–7.
- Drgona L, Khachatryan A, Stephens J, et al. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of *Aspergillus* and *Candida* species. *Eur J Clin Microbiol Infect Dis*. 2014;33:7–21.
- Muñoz P, Valerio M, Vena A, Bouza E. Antifungal stewardship in daily practice and health economic implications. *Mycoses*. 2015;58(S2):14–25.
- Lachenmayr SJ, Berking S, Horns H, Strobach D, Ostermann H, Berger K. Antifungal treatment in haematological and oncological patients: need for quality assessment in routine care. *Mycoses*. 2018;6:1–8.
- Global Action Fund for Fungal Infections. 95–95 by 2025. Improving outcomes for patients with fungal infections across the world: a roadmap for the next decade; May 2015. <http://www.gaffi.org/roadmap/> [accessed May 2018].
- Valerio M, Muñoz P, Rodríguez CG, et al. Antifungal stewardship in a tertiary-care institution: a bedside intervention. *Clin Microbiol Infect*. 2015;21:492, e1–492.e9.
- Catálogo Universal de Servicios de Salud 2016 and 2018. <https://www.gob.mx/salud%7Cseguiopopular/articulos/catalogo-universal-de-servicios-de-salud-causes-2018> [accessed 27.05.18].
- De Pauw B, Walsh TJ, Donnelly JP, et al., Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. *Clin Infect Dis*. 2008;46:1813–21.
- Organization for the Economic Co-operation and Development (OECD). [webpage stats.oecd.org](http://webpage.stats.oecd.org) [accessed December 2017].
- Corzo-Leon DE, Alvarado-Matute T, Colombo AL, et al. Surveillance of *Candida* spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals. *PLoS One*. 2014;9:e97325.
- Gaona-Flores VA, Campos-Navarro L, Cervantes-Tovar R, Alcalá-Martínez E. The epidemiology of fungemia in an infectious diseases hospital in Mexico city: a 10-year retrospective review. *Med Mycol*. 2016;54:600–4.
- Baptista Rosas RC, Riquelme M. Epidemiología de la coccidioidomycosis en México. *Rev Iberoam Micol*. 2007;24:100–5.
- Anuarios de morbilidad. DGE.SSA. <http://www.epidemiologia.salud.gob.mx/anuario/html/anuarios.html> [accessed 20.05.18].
- Adams D, Fullerton K, Jajosky R, et al. Summary of notifiable infectious diseases and conditions – United States, 2013. *MMWR Morb Mortal Wkly Rep*. 2015;1–122.
- Report MW. Increase in reported coccidioidomycosis – United States, 1998–2011. *MMWR Morb Mortal Wkly Rep*. 2013;62:217–21.
- Benedict K, Derado G, Mody RK. Histoplasmosis-associated hospitalizations in the United States, 2001–2012. *Open Forum Infect Dis*. 2016;3:1–4.
- Armstrong PA, Jackson BR, Haselow D, et al. Multistate epidemiology of histoplasmosis United States, 2011–2014. *Emerg Infect Dis*. 2018;24:425–31.
- Nucci M, Carlesse F, Cappellano P, et al. Earlier diagnosis of invasive fusariosis with *Aspergillus serum galactomannan* testing. *PLoS One*. 2014;9:1–5.
- Zilberberg MD, Nathanson BH, Harrington R, Spalding JR, Shorr AF. Epidemiology and outcomes of hospitalizations with invasive *Aspergillus* in the United States, 2009–2013. *Clin Infect Dis*. 2018;2009–13.
- Secretaría de Salud. Secretaría de Salud, Dirección General de Información en Salud. Sistema Nacional de Información en Salud y Catálogo Único de Establecimientos en Salud (CLUES). www.dgis.salud.gob.mx/contenidos/intercambio/clues_gobmx.html [accessed May 2018].
- Clancy CJ, Nguyen MH. Finding the missing 50% of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. *Clin Infect Dis*. 2013;56:1284L 92.

25. Adenis A, Nacher M, Hanf M, et al. HIV-associated histoplasmosis early mortality and incidence trends: from neglect to priority. *PLoS Negl Trop Dis*. 2014;8:6–10.
26. WHO. National Medicines List/Formulary/Standard Treatment Guidelines. <http://www.who.int/medicines/publications/essentialmedicines/en/> [accessed May 2018].
27. Catálogo Universal de Servicios de Salud, CAUSES 2018. <https://www.gob.mx/salud%7Cseguropopular/articulos/catalogo-universal-de-servicios-de-salud-causes-2018> [accessed 27.05.18].
28. Rex JH, Walsh TJ. Editorial response: estimating the true cost of amphotericin B. *Clin Infect Dis*. 1999;29:1408–10.
29. SAT (Servicio de Administración Tributaria). http://www.sat.gob.mx/informacion_fiscal/tablas_indicadores/Paginas/salarios_minimos.aspx [accessed 27.05.18].
30. Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal therapy and its variable cost. *J Antimicrob Chemother*. 2016;71:3599–606.
31. COFEPRIS. <https://www.gob.mx/cofepris/documentos/registros-sanitarios-medicamentos> [accessed 27.05.18].
32. Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. *N Engl J Med*. 2018;378:17–004.
33. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. *Med Mycol*. 2008;46:393–5.
34. Rtveldadze K, Marsh T, Barquera S, et al. Obesity prevalence in Mexico: impact on health and economic burden. *Public Health Nutr*. 2014;17:233–9.
35. Menzin J, Meyers JL, Friedman M, et al. The economic costs to United States hospitals of invasive fungal infections in transplant patients. *Am J Infect Control*. 2011;39:e15–20.
36. Ashley ED, Drew R, Johnson M, et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. *Pharmacotherapy*. 2012;32:890–901.
37. Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. *Am J Heal Pharm*. 2009;66:1711–7.
38. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. *Clin Infect Dis*. 2001;32:686–93.
39. Chertow GM. Acute kidney injury, mortality length of stay, and costs in hospitalized patients. *J Am Soc Nephrol*. 2005;16:3365–70.